Literature DB >> 23018838

EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas.

Francesca Ripamonti1, Luisa Albano, Anna Rossini, Serena Borrelli, Sonia Fabris, Roberto Mantovani, Antonino Neri, Andrea Balsari, Alessandra Magnifico, Elda Tagliabue.   

Abstract

Many squamous cell carcinomas (SCCs) are characterized by high levels of EGFR and by overexpression of the ΔNp63α isoform. Here, we investigated the regulation of ΔNp63α expression upon EGFR activation and the role of the EGFR-ΔNp63α axis in proliferation of SCC tumor-initiating cells (TICs). SCC cell lines A-431, Cal-27, and SCC-25 treated with EGF showed a time-dependent increase in ΔNp63α expression at the protein and mRNA levels, which was blocked by the tyrosine kinase inhibitor (TKI) Lapatinib. RNA interference experiments suggested the role of STAT3 in regulating ΔNp63α expression downstream of EGFR. Inactivation of EGFR by the monoclonal antibody Cetuximab and RNA interference against STAT3 or ΔNp63α impaired the TICs ability to grow under non-differentiating conditions. Radiation treatment, which triggers EGFR activation, induced ΔNp63α accumulation without affecting TICs proliferation, whereas the combination Cetuximab plus radiation significantly reduced TICs growth under non-differentiating conditions. Together, our findings provide evidence that ΔNp63α expression is regulated by EGFR activation through STAT3 and that the EGFR-ΔNp63α axis is crucial for proliferation of TICs present in SCCs.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23018838     DOI: 10.1002/jcp.24238

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

Review 1.  p63-related signaling at a glance.

Authors:  Matthew L Fisher; Seamus Balinth; Alea A Mills
Journal:  J Cell Sci       Date:  2020-09-11       Impact factor: 5.285

2.  Combined targeting of EGFR and HER2 against prostate cancer stem cells.

Authors:  Anna Rossini; Marta Giussani; Francesca Ripamonti; Piera Aiello; Viola Regondi; Andrea Balsari; Tiziana Triulzi; Elda Tagliabue
Journal:  Cancer Biol Ther       Date:  2020-02-23       Impact factor: 4.742

Review 3.  Pathway Regulation of p63, a Director of Epithelial Cell Fate.

Authors:  Kathryn Yoh; Ron Prywes
Journal:  Front Endocrinol (Lausanne)       Date:  2015-04-28       Impact factor: 5.555

4.  Tuberatolide B Suppresses Cancer Progression by Promoting ROS-Mediated Inhibition of STAT3 Signaling.

Authors:  Youn Kyung Choi; Junseong Kim; Kang Min Lee; Yu-Jeong Choi; Bo-Ram Ye; Min-Sun Kim; Seong-Gyu Ko; Seung-Hong Lee; Do-Hyung Kang; Soo-Jin Heo
Journal:  Mar Drugs       Date:  2017-02-25       Impact factor: 5.118

5.  STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis.

Authors:  Stephen D'Amico; Jiaqi Shi; Benjamin L Martin; Howard C Crawford; Oleksi Petrenko; Nancy C Reich
Journal:  Genes Dev       Date:  2018-08-22       Impact factor: 11.361

6.  Exosome-mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non-small cell lung cancer.

Authors:  Wei Zhang; Xinrui Cai; Jie Yu; Xuxiang Lu; Qiuhai Qian; Weibin Qian
Journal:  Int J Oncol       Date:  2018-05-17       Impact factor: 5.650

7.  Identifying pathways regulating the oncogenic p53 family member ΔNp63 provides therapeutic avenues for squamous cell carcinoma.

Authors:  Zuzana Pokorna; Jan Vyslouzil; Borivoj Vojtesek; Philip J Coates
Journal:  Cell Mol Biol Lett       Date:  2022-02-23       Impact factor: 5.787

8.  Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling.

Authors:  Youn Kyung Choi; Sung-Gook Cho; Sang-Mi Woo; Yee Jin Yun; Sunju Park; Yong Cheol Shin; Seong-Gyu Ko
Journal:  Mediators Inflamm       Date:  2014-05-25       Impact factor: 4.711

Review 9.  STAT3, stem cells, cancer stem cells and p63.

Authors:  Michaela Galoczova; Philip Coates; Borivoj Vojtesek
Journal:  Cell Mol Biol Lett       Date:  2018-03-22       Impact factor: 5.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.